$11.46
▲ +0.3% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
Overview
52-week range
$2.75
$13
89% of range
Avg surprise (last 3)
+25.8%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
84%
EM ±13.1% · $11 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.18 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.14 | $-0.22 | +36.4% | +6.7% | +0.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.12 | $-0.17 | +29.4% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.15 | $-0.17 | +11.8% | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.17 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.10 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.11 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.14 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $8M | — | $9M | $17M | $4M | — | $7M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-63M | $-58M | — | $-76M | $-50M | $-63M | — | $-94M |
| Net income | $-55M | $-43M | — | $-57M | $-35M | $-46M | — | $-51M |
| EPS (diluted) | $-0.18 | $-0.14 | — | $-0.19 | $-0.12 | $-0.15 | — | $-0.17 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $120M | $77M | $129M | $83M | $92M | $159M | $156M | $127M |
| Inventory | $8M | $8M | $6M | — | — | — | — | — |
| Total current assets | $679M | $665M | $728M | $695M | $742M | $765M | $751M | $743M |
| Total assets | $1.31B | $1.31B | $1.36B | $1.36B | $1.40B | $1.34B | $1.36B | $1.39B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $412M | $369M | $390M | $392M | $395M | $321M | $304M | $315M |
| Total equity | $896M | $938M | $967M | $964M | $1.01B | $1.02B | $1.06B | $1.08B |